HeimGNLX • NASDAQ
add
Genelux Corp
Við síðustu lokun
2,77 $
Dagbil
2,76 $ - 2,86 $
Árabil
2,26 $ - 8,54 $
Markaðsvirði
125,01 m. USD
Meðalmagn
211,85 þ.
V/H-hlutf.
-
A/V-hlutfall
-
Aðalkauphöll
NASDAQ
Viðskiptafréttir
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (USD) | des. 2025info | Breyting á/á |
|---|---|---|
Tekjur | 8,00 þ. | — |
Rekstrarkostnaður | 9,42 m. | -3,36% |
Nettótekjur | -9,25 m. | -3,02% |
Hagnaðarhlutfall | -115,59 þ. | — |
Hagnaður á hvern hlut | -0,24 | 7,69% |
EBITDA | -9,35 m. | 3,50% |
Virkt skatthlutfall | — | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (USD) | des. 2025info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 14,60 m. | -52,76% |
Heildareignir | 19,03 m. | -45,19% |
Heildarskuldir | 7,48 m. | -11,36% |
Eigið fé alls | 11,54 m. | — |
Útistandandi hlutabréf | 44,37 m. | — |
Eiginfjárgengi | 8,94 | — |
Arðsemi eigna | -106,92% | — |
Ávöxtun eigin fjár | -140,71% | — |
Peningaflæði
Breyting á handbæru fé
| (USD) | des. 2025info | Breyting á/á |
|---|---|---|
Nettótekjur | -9,25 m. | -3,02% |
Handbært fé frá rekstri | -6,20 m. | -44,10% |
Reiðufé frá fjárfestingum | 6,56 m. | -1,65% |
Reiðufé frá fjármögnun | 276,00 þ. | 203,30% |
Breyting á handbæru fé | 641,00 þ. | -73,97% |
Frjálst peningaflæði | -3,12 m. | -172,80% |
Um
Genelux Corporation is a publicly traded late clinical-stage company developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity.
The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.
The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME. Wikipedia
Stofnsett
2001
Höfuðstöðvar
Vefsvæði
Starfsfólk
26
